Skip to main content


  • Poster presentation
  • Open Access

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 7,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16,
  • 13,
  • 17 and
  • 1
Pediatric Rheumatology20119 (Suppl 1) :P181

  • Published:


  • Juvenile Idiopathic Arthritis
  • Clinical Practice Guideline
  • Biologic Agent
  • Scientific Society
  • Consensus Statement


To improve the quality of care for patients with JIA, standardization of treatment is mandatory. We present a clinical practice guideline (CPG) for the treatment of JIA. It is based on the existing CPG of 2005* and 2008# (*published as book chapter; #peer reviewed publication: Clinical Research and Practice in Paediatrics 2008; 220: 392 - 402).


We performed a systematic literature analysis in PubMed (deadline: 15th January 2010, terms "juvenile idiopathic (rheumatoid) arthritis", "therapy", limits: “humans”, “published in the last 3 years”, “all child 0-18 years”, “clinical trial”) and evaluated relevant studies for quality of methodology. A formal consensus process, i.e. Nominal group technique and Delphi method, was conducted at three moderated consensus conferences at Düsseldorf or Krefeld (Germany) on May 9th, 2007, August 1st, 2007 and January 15th, 2010. Conferences were attended by 95% of the representatives who had been nominated by their scientific society or organizations.


15 consensus statements and key notes regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (presented on the poster).


Currently, we recommend that JIA is treated with NSAR followed by local GC and/ or MTX as first line treatment. Other interventions e. g. the role of biologic agents, physiotherapy, and arthroscopy are discussed strictly on the basis of literature available. Our CPG will require a frequent update, as the number of randomized trials is increasing and the new potential drugs will become available.

Authors’ Affiliations

HELIOS Children’s Hospital, Krefeld, Germany
German Federal Armed Forces central hospital, Koblenz, Germany
Rheumazentrum Oberammergau, Oberammergau, Germany
Olgahospital, Stuttgart, Germany
Klinikum Eilbeck, Hamburg, Germany
University Children’s Hospital, Muenster, Germany
St. Josef Stift, Sendenhorst, Germany
St. Franziskus Hospital, Münster, Germany
Asklepios Children’s Hospital, St. Augustin, Germany
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Marburg, Germany
University Department of Orthopaedics, Duesseldorf, Germany
Deutsche Rheuma Liga e.V., Bonn, Germany
German Centre for Paediatric and Adolescent Rheumatology, Garmisch Partenkirchen, Germany
University Department of Endocrinology, Diabetology and Rheumatology, Duesseldorf, Germany
Berlin-Schoeneberg, Germany
University Department of Surgical Research, Marburg, Germany
University Children’s Hospital, Aachen, Germany


© Dueckers et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.